Better management and treatment of neurological diseases

Management and treatment of neurological diseases is one of the biggest challenges facing medicine today. EU-funded researchers are developing computational tools to improve understanding of how such diseases progress as a means to help treat patients.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


 

Published: 22 June 2018  
Related theme(s) and subtheme(s)
Health & life sciencesHealth & ageing  |  Medical research  |  Neuroscience  |  Rare & orphan diseases
Research policyHorizon 2020
Countries involved in the project described in the article
Belgium  |  France  |  Italy  |  Netherlands  |  Switzerland  |  United Kingdom
Add to PDF "basket"

Better management and treatment of neurological diseases

Image

© ipopba #208730889, source: fotolia.com, 2018

With around 5 million patients in the EU, annual socio-economic costs of Alzheimer's disease exceed EUR 200 billion, while other types of dementia combined have a similar cost. These figures will rise rapidly due to Europe’s ageing population. Although rare, with about two cases per million people a year (rising to five per million for the over 60s), prion diseases, such as Creutzfeldt-Jakob disease, are devastating, with a life expectancy of under a year.

Multiple sclerosis affects more than 2 million people worldwide, around two-thirds of whom are female. Onset is often early, typically affecting patients from 20 to 35 years old. Prevalence is high in Europe, where up to 1 400 people per million are affected. Neurocognitive disorders affect 27 % of Europe’s population and 5 % of children suffer from attention deficit hyperactivity disorders and autism. Childhood and adult depression are increasing.

The EU-funded EuroPOND project is collecting data from a wide sample of neurological patients in order to develop advanced statistical and computational modelling tools. The tools create pictures showing how neurological diseases develop and vary among individuals.

By making it possible to identify groups of patients with similar characteristics, this approach supports formulation of new evidence-based treatments. It will also improve prognosis by better matching patients with treatments and care plans.

“EuroPOND models strike a balance between imposed knowledge of disease features and patterns learned from data,” says scientific manager and senior researcher Neil Oxtoby, of University College London, UK. “The resulting models are both predictive of disease progression in individuals and informative in terms of revealing underlying biological patterns.”

Daniel Alexander, EuroPOND coordinator, adds: “In this way, our new models and algorithms enable us to stratify people into groups, and to design and assign treatments appropriately – towards the goal of precision medicine – as well as gaining new understanding of the disease landscape for future drug development and healthcare delivery.”

Complex diseases

EuroPOND tackles the inherent complexity of neurological disease, and overlap between such diseases in terms of symptoms and pathologies, by taking account of a variety of clinical and biomedical data. These cover aspects including risk factors, biomarkers indicating the presence of a condition, and neurological interactions.

Creation of a multidisciplinary, pan-European consortium has been vital for developing robust and consistent tools and computational models spanning a sufficiently wide range of conditions. This allows models for different diseases to be combined so as to provide an unprecedented view of broader disease classes and, ultimately, neurological disease as a whole.

Revolutionising research

The deeper understanding of neurological diseases generated by EuroPOND’s results is helping to revolutionise research in the field. Aside from that, two key impacts are expected by the time the project ends in December 2019: more rapid and economical clinical trials, and faster diagnosis through computer-assisted evaluation of patients.

“The next step is to create similar tools to bring our techniques to the pharmaceutical industry and aid future clinical trials,” says Oxtoby. “We are prototyping two software-based tools for computer-assisted evaluation of patients and more efficient clinical trials, built upon our methodological innovations. We are also working to include the computational modelling tools in cloud-based image-analysis systems that supply radiological assessments to clinicians, thereby providing a platform for widespread uptake.”

Project details

  • Project acronym: EuroPOND
  • Participants: UK (Coordinator), France, Netherlands, Italy, Switzerland, Belgium
  • Project number: 666992
  • Total costs: € 5 498 612
  • EU contribution: € 4 975 862
  • Duration: January 2016 to December 2019

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details